Connect with us

Hi, what are you looking for?

Jewish Business News


Teva Settles Cephalon Case With FTC for $1.2 Billion Over block generic drug competition

Teva CEO Erez Vigodman

Teva Pharmaceutical Industries Ltd. has agreed to pay $1.2 billion in a settlement with the U.S. Federal Trade Commission (FTC), resolving claims that Cephalon Inc. blocked generic drug competition. Teva acquired Cephalon in 2012.

The FTC will hold the settlement money to compensate drug purchasers, including wholesalers, pharmacies and insurers, who overpaid for the sleep-disorder drug Provigil because of Cephalon’s illegal conduct, the commission said.

In a statement the FTC said: “Today’s landmark settlement is an important step in the FTC’s ongoing effort to protect consumers from anti-competitive pay-for-delay settlements.”

The settlement comes ahead of proceedings that were scheduled to begin Monday in a Philadelphia federal court.

Teva made way for its $40.1 billion takeover of rival drug maker Mylan NV in a deal that would add to a record period of consolidation in the pharmaceutical industry.

READ our report on that matter HERE

Click to comment



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...